Sairah Ahmed, MD

Sairah Ahmed, MD, associate professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the continued investigations of axicabtagene ciloleucel (axi-cel; Yescarta), a chimeric antigen receptor (CAR) T-cell therapy used in multiple types of lymphoma, including patients with mantle cell lymphoma, transformed follicular lymphoma, diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and high grade B-cell lymphoma.

Right now, there are many ongoing clinical trials looking at axi-cel in early-stage disease, and others investigating how to reduce toxicity while improving efficacy when using axi-cel in patients with lymphoma. Some of these trials include an investigation of axi-cel in patients with relapsed/refractory central nervous system lymphoma (NCT04608487) and as second-line therapy in patients with relapsed/refractory aggressive B lymphoma (NCT04531046). Ahmed thinks that this pinpoints a population that should most likely have a more aggressive treatment modality and potentially have some other treatment prior to or after CAR T-cell therapy to improve outcomes.

Although the research of CAR T-cell treatment is still in an earlier stage compared with some other cancer therapies, Ahmed says there needs to be a continued effort to evaluate which patients do well versus patients who do not do well and try to tailor treatment to those particular populations.

Videos

Sairah Ahmed, MD, discusses the continued investigations of axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy used in multiple types of lymphoma.

Sairah Ahmed, MD | Authors

Articles

Research Ongoing for CAR T-Cell Therapy Axi-Cel in Lymphoma